Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2024 / Articles / Nov / Being Proactive About Healthcare Challenges
Business & Regulation Trends & Forecasts Vaccines Sponsored

Being Proactive About Healthcare Challenges

Why we need to shift from reactive to proactive measures in tackling global health challenges.

11/22/2024 1 min read

Share

What we asked: “Looking ahead to the next 5–10 years, what will be the key disruptors and/or what can be improved upon in the pharma industry?”

Response from: Derek Wallace, President, Takeda Vaccine Business Unit

One area of improvement is clear to me: a need to shift from reactive to proactive measures in tackling global health challenges.

Throughout my career in vaccine development, I have witnessed firsthand the transformative impact that proactive strategies can have on combatting complex health challenges. A great example – and opportunity – is in infectious diseases such as dengue, malaria, and chikungunya. As mosquito-borne diseases, they are often exacerbated by the weather fluctuations we are experiencing globally, underscoring the undeniable impact of climate change on human health. We’ve seen this play out in headlines across the world tied to major outbreaks and the growing threat of these diseases

But what does being proactive mean? For mosquito-borne diseases such as dengue, we must continue to invest in vaccination, while improving existing tactics such as surveillance, strengthening public health systems, and promoting widespread education and community engagement efforts to control and eliminate vectors. It's this preparation that helps ensure readiness before epidemics or outbreaks strike.

In addition, we must recognize that the effectiveness of preventative measures hinges on global collaboration. Diseases do not respect borders and are a global problem. A united approach involving health authorities, the private sector, communities at risk, public health organizations, and government bodies, is vital. These collaborative efforts will help foster an environment where coordinated strategies can be effectively applied and innovative solutions can emerge.

This shift is crucial not only for managing mosquito-borne diseases but also for ensuring the resilience of our health systems in the face of new health challenges, whether tied to climatic changes or other future threats that will undoubtedly arise.

Read over 100 other views on the future of the pharma industry on our special web page.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Big Bad Pharma?
Business Practice Trends & Forecasts
Big Bad Pharma?

December 1, 2014

0 min read

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Access All Areas
Business Practice Trends & Forecasts
Access All Areas

December 1, 2014

0 min read

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Care to ‘Patent Dance’?
Business Practice Trends & Forecasts
Care to ‘Patent Dance’?

December 1, 2014

0 min read

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.